Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, Gatopoulou A, Karatzas P, Kopylov U, Michalopoulos G, Michopoulos S, Navaneethan U, Rubin DT, Siffledeen J, Singh A, Soufleris K, Stein D, Demuth D, Mantzaris GJ. Bressler B, et al. Among authors: kopylov u. J Crohns Colitis. 2021 Oct 7;15(10):1694-1706. doi: 10.1093/ecco-jcc/jjab058. J Crohns Colitis. 2021. PMID: 33786600 Free PMC article.
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
Kopylov U, Mantzaris GJ, Katsanos KH, Reenaers C, Ellul P, Rahier JF, Israeli E, Lakatos PL, Fiorino G, Cesarini M, Tsianos EV, Louis E, Ben-Horin S. Kopylov U, et al. Aliment Pharmacol Ther. 2011 Feb;33(3):349-57. doi: 10.1111/j.1365-2036.2010.04523.x. Epub 2010 Dec 1. Aliment Pharmacol Ther. 2011. PMID: 21118397 Free article.
Travel-associated health risks for patients with inflammatory bowel disease.
Ben-Horin S, Bujanover Y, Goldstein S, Nadler M, Lang A, Kopylov U, Katz L, Lahat A, Schwartz E, Avidan B. Ben-Horin S, et al. Among authors: kopylov u. Clin Gastroenterol Hepatol. 2012 Feb;10(2):160-5, 165.e1. doi: 10.1016/j.cgh.2011.10.025. Epub 2011 Nov 2. Clin Gastroenterol Hepatol. 2012. PMID: 22056299
Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.
Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, Awadie H, Weiss B, Chowers Y. Ben-Horin S, et al. Among authors: kopylov u. Clin Gastroenterol Hepatol. 2013 Apr;11(4):444-7. doi: 10.1016/j.cgh.2012.10.020. Epub 2012 Oct 24. Clin Gastroenterol Hepatol. 2013. PMID: 23103905
Optimizing anti-TNF treatments in inflammatory bowel disease.
Ben-Horin S, Kopylov U, Chowers Y. Ben-Horin S, et al. Among authors: kopylov u. Autoimmun Rev. 2014 Jan;13(1):24-30. doi: 10.1016/j.autrev.2013.06.002. Epub 2013 Jun 19. Autoimmun Rev. 2014. PMID: 23792214 Review.
259 results